NCT03866967View on ClinicalTrials.gov

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

March 13, 2021

Study Completion Date

March 22, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

AK105

intravenous (IV) infusion

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

200032

FuDan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Tiancheng, Inc

OTHER

lead

Akeso

INDUSTRY

NCT03866967 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter